Genzyme has added Third Wave Technologies' UGT1A1 colorectal cancer test to its suite of recent pharmacogenomics-related products, and it plans to popularize and sell these tests using a shared marketing strategy.

"We're really promoting the personalized medicine aspect in both 2005 and 2006," Genzyme spokesperson Celeste Chenet-Monte told Pharmacogenomics Reporter this week. "Our pipeline for 2006 is really devoted exclusively to pharmacogenetic-type tests."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.